Skip to main content
. 2022 Jul 5;13:3875. doi: 10.1038/s41467-022-31479-x

Fig. 5. Treatment of subcutaneous MRSA biofilm infected mice by HCM NPs.

Fig. 5

a Schematic illustration of the experimental procedure for treating MRSA biofilm infected mice. b Fluorescence images of MRSA biofilm infected mice after in situ injection of HCM NPs (Ce6: 100 μg/mL, 50 μL) in normal tissues (left side of thigh) and biofilm infected tissues (right side of thigh), respectively. c Fluorescence images of MRSA biofilm infected mice after i.v. injection of HCM NPs (Ce6 = 4 mg/kg; MNZ = 2 mg/kg). d Representative immunofluorescence images of HIF-1α (green) and VEGF (yellow) in MRSA biofilm infected tissues after various treatments for 4 d. Scale bar is 400 μm. The percentage of HIF-1α+ (e) and VEGF+ (f) area in various treatment groups calculated from the immunofluorescence images (n = 10 biologically independent samples; mean ± SD). Photographs of the infected tissues (g) and infected area (h) of the mice after various treatments (n = 5 biologically independent samples; mean ± SD). i Quantification of viable bacteria inside biofilm-infected tissues at 8 d post-treatment (n = 5 biologically independent samples; mean ± SD). j Photographs of MRSA colonies from infected tissues at 8 d post-treatment. k H&E and Masson’s trichrome stained slices of the infected tissues from mice at 8th d post-treatment. Scale bar is 500 μm. Statistical significance was analyzed via one-way ANOVA with a Tukey post-hoc test. Source data are provided as a Source Data file.